```html

Tylosis (Candidal Esophagitis) – A Patient‑Friendly Guide

Overview

Tylosis, more commonly referred to as candidal esophagitis, is an inflammation of the esophagus caused by overgrowth of the fungus Candida (usually Candida albicans). The condition is part of a broader spectrum of esophageal infections and is sometimes called “fungal esophagitis.” It typically occurs in people whose immune systems are compromised, but it can also affect otherwise healthy individuals under certain circumstances.

Who it affects

• People with HIV/AIDS (especially CD4 counts < 200 cells/µL).
• Patients receiving chemotherapy, radiation, or long‑term corticosteroids.
• Individuals with organ transplants or other forms of immunosuppression.
• Those taking broad‑spectrum antibiotics, proton‑pump inhibitors (PPIs), or inhaled steroids for asthma.
• Adults over 50 years old, especially with diabetes or chronic lung disease.

Prevalence

In the United States, candidal esophagitis accounts for roughly 5‑10 % of all cases of esophagitis among immunocompromised patients. Among persons living with HIV, the prevalence ranges from 15 % to 30 % before the widespread use of antiretroviral therapy (ART) and has fallen to < 8 % in the ART era (NIH, 2022). Exact worldwide numbers are difficult to obtain because the condition is often diagnosed incidentally during endoscopy.

Symptoms

Symptoms can be mild or severe and may develop gradually. Common complaints include:

• Odynophagia – pain or burning sensation while swallowing.
• Dysphagia – difficulty swallowing solid foods or liquids.
• Retrosternal pain – a deep, pressure‑like pain behind the breastbone.
• Chest discomfort that may be mistaken for heartburn or cardiac pain.
• Unexplained weight loss due to avoidance of food.
• Nausea or vomiting – especially if the inflammation is extensive.
• Fever – may occur in severely immunocompromised patients.
• Hoarseness or chronic cough – when the infection spreads to the upper airway.
• Sore throat – often reported as “raw” or “scratchy.”

In many cases, especially in early disease, patients may experience only one or two of these symptoms, which can lead to delayed diagnosis.

Causes and Risk Factors

Underlying cause

Candidal esophagitis is caused by an overgrowth of Candida species in the esophageal mucosa. Candida is a normal part of the oral and gastrointestinal flora; however, when the immune system is weakened or the local environment changes, the fungus can proliferate and invade the lining of the esophagus.

Key risk factors

• Immunosuppression – HIV/AIDS, solid‑organ or bone‑marrow transplantation, chemotherapy, high‑dose steroids.
• Antibiotic exposure – broad‑spectrum antibiotics reduce bacterial competition, allowing Candida to flourish.
• Acid‑suppressive therapy – PPIs and H2 blockers raise gastric pH, creating a more hospitable environment for fungi.
• Diabetes mellitus – hyperglycemia impairs neutrophil function.
• Smoking and alcohol – irritate the mucosa and alter local immunity.
• Inhaled corticosteroids – especially when not rinsed out after use.
• Elderly age – natural decline in immune surveillance.

Diagnosis

Because the symptoms overlap with reflux disease, bacterial esophagitis, and even malignancy, a careful diagnostic work‑up is essential.

Clinical evaluation

• Detailed medical history focused on immune status, medication use, and recent antibiotic therapy.
• Physical examination looking for oral thrush, weight loss, or signs of systemic infection.

Endoscopic examination

Upper gastrointestinal (GI) endoscopy (esophagogastroduodenoscopy, EGD) is the gold standard. Typical endoscopic findings include:

• White, raised plaques adherent to the esophageal mucosa that may be scraped off, revealing an ulcerated base.
• Occasionally, ulcerations without plaques (especially in severe disease).

Biopsy and laboratory studies

• Histopathology – Tissue samples stained with PAS (periodic acid‑Schiff) or GMS (Grocott‑Methenamine Silver) reveal yeast and pseudohyphae.
• Culture – Allows identification of Candida species and antifungal susceptibility testing.
• Rapid antigen or PCR tests – Emerging tools that can provide quicker results, though not yet routine.

Additional tests (when indicated)

• Complete blood count (CBC) and CD4 count for HIV patients.
• Serum glucose and HbA1c for diabetes screening.
• Chest X‑ray or CT if complications (e.g., perforation) are suspected.

Treatment Options

Treatment aims to eradicate the fungal infection, relieve symptoms, and address underlying risk factors.

Antifungal medications

First‑line agents are oral azoles. Choice depends on severity, drug interactions, and local resistance patterns.

• Fluconazole – 200 mg on day 1, then 100–200 mg daily for 2–3 weeks. Most effective for C. albicans and well‑tolerated.
• Itraconazole – 200 mg twice daily (solution) for 3 weeks; useful for fluconazole‑resistant strains.
• Voriconazole – 200 mg twice daily for resistant infections or when oral azoles fail; monitor liver function.
• Echinocandins (caspofungin, micafungin) – IV therapy for severe disease or when azoles are contraindicated.

Intravenous therapy

Patients unable to swallow, those with severe esophageal ulceration, or those with systemic candidemia may require IV amphotericin B or an echinocandin for 7–14 days before switching to oral therapy.

Adjunctive measures

• Stop or taper unnecessary antibiotics, PPIs, and inhaled steroids when possible.
• Optimize glycemic control in diabetics.
• Treat oral thrush concurrently (e.g., nystatin suspension).

Lifestyle and supportive care

• Soft, bland diet (e.g., smoothies, oatmeal) while dysphagia improves.
• Hydration to keep secretions thin and facilitate swallowing.
• Pain control with acetaminophen or low‑dose NSAIDs if no contraindications.

Living with Tylosis (candidal esophagitis)

Daily management tips

• Medication adherence – Complete the entire antifungal course, even if symptoms improve within a few days.
• Oral hygiene – Brush twice daily, rinse with chlorhexidine or nystatin if oral thrush is present.
• Nutrition – Small, frequent meals; avoid very hot, spicy, or acidic foods that can exacerbate pain.
• Monitor symptoms – Keep a diary of swallowing difficulty, weight changes, and fever.
• Follow‑up appointments – Repeat endoscopy is usually not needed if symptoms resolve, but a second endoscopy may be ordered for patients with persistent pain or risk of malignancy.
• Vaccinations – Stay up‑to‑date on influenza and pneumococcal vaccines to reduce respiratory infections that can further suppress immunity.

Psychosocial aspects

Chronic esophageal symptoms can affect mood and social eating. Consider support groups for people living with HIV, transplant recipients, or chronic illness. Counseling or cognitive‑behavioral therapy can help manage anxiety related to swallowing.

Prevention

• Limit unnecessary antibiotics – Use the narrowest spectrum agent for the shortest effective duration.
• Use PPIs judiciously – Reserve for validated indications and step down to H2 blockers when possible.
• Rinse mouth after inhaled steroids – Spit out the medication and rinse with water.
• Control blood sugar – Aim for HbA1c < 7 % (or target set by your provider).
• Maintain good oral hygiene – Daily brushing, flossing, and regular dental visits.
• Adhere to HIV treatment – Effective ART keeps CD4 counts higher, dramatically reducing opportunistic infections.
• Nutrition – Adequate protein and micronutrients support immune function.

Complications

If left untreated or if treatment fails, candidal esophagitis can lead to serious sequelae:

• Esophageal ulceration – May cause bleeding (hematemesis) or perforation.
• Stricture formation – Healing can lead to narrowing, requiring dilation.
• Fungal dissemination – Candida can enter the bloodstream, causing candidemia, endocarditis, or involvement of other organs.
• Weight loss and malnutrition – Chronic dysphagia reduces caloric intake.
• Secondary infection – Ulcerated mucosa can be a portal for bacterial superinfection.

When to Seek Emergency Care

References

• Mayo Clinic. “Candidal Esophagitis.” https://www.mayoclinic.org. Accessed May 2026.
• CDC. “Fungal Diseases: Esophageal Candidiasis.” https://www.cdc.gov. Updated 2023.
• NIH National Institute of Allergy and Infectious Diseases. “Opportunistic Infections in HIV.” 2022.
• World Health Organization. “Guidelines for the Management of Opportunistic Fungal Infections.” 2021.
• Cleveland Clinic. “Candida Esophagitis: Symptoms, Diagnosis, Treatment.” https://my.clevelandclinic.org. Accessed May 2026.
• Jenkins, D. et al. “Azole‑Resistant Candida in Immunocompromised Hosts.” *Clinical Infectious Diseases*, vol 73, no 5, 2022, pp 923‑931.

```